PRESS RELEASE 2023
-
Ferring Announces Positive Topline Phase 3 Results for SI-6603, an Investigational Treatment for Lumbar Disc Herniation
The primary endpoint was met: SI-6603 showed statistically significant improvement in worst leg pain score versus control at 13 weeks after injection. SI-6603 was generally well-tolerated. Ferring’s clinical development partner, Seikagaku Corporation, plans to proceed with preparation for a Biolo...
-
Four Analyses of Data for REBYOTA™ (fecal microbiota, live – jslm), the First FDA-Approved Microbiome-Based Treatment for the Prevention of Recurrent C. difficile Infection, Presented at DDW 2023
Data presentations highlight Ferring’s microbiome leadership and commitment to ongoing research Analyses review safety and efficacy data across various patient populations with co-morbidities and when treatment is administered by colonoscopy Additional analysis evaluates shifts in microbiom...
-
Retrospective Analysis of Data Evaluating Safety and Efficacy of REBYOTA™ (fecal microbiota, live – jslm) in a Real-World Patient Population with Comorbidities and Risk Factors Published in Open Forum Infectious Diseases
REBYOTA is indicated for the prevention of recurrence of Clostridioides difficile (C. diff) infection in individuals 18 years of age and older, following antibiotic treatment for recurrent C. diff infection Analysis is the first to evaluate safety and efficacy of REBYOTA in a real-world populatio...
-
Ferring Pharmaceuticals Recognizes National Infertility Awareness Week®
National Infertility Awareness Week® seeks to inspire, educate and activate the fertility community to speak up about infertility to help drive change. Parsippany, NJ, USA – April 24, 2023 – Ferring Pharmaceuticals today announced its unwavering support of National Infertility Awareness Week® (N...
-
Ferring to Present Analyses of Data for REBYOTA™ (fecal microbiota, live – jslm), the First FDA-Approved Microbiome-Based Treatment for the Prevention of Recurrent C. difficile Infection, at DDW 2023
Parsippany, NJ, USA – April 18, 2023 – Ferring Pharmaceuticals today announced it will present analyses of data for REBYOTA™ (fecal microbiota, live – jslm) at Digestive Disease Week® (DDW 2023). The congress will take place May 6-9, 2023, in Chicago, Ill. REBYOTA is the first microbiome-based tr...
-
Ferring Pharmaceuticals Announces Availability of REBYOTA™ (fecal microbiota, live – jslm) – the First and Only FDA-Approved Microbiome-Based Treatment for the Prevention of Recurrence of C. diff Infection in Adults
REBYOTA is indicated for the prevention of recurrence of Clostridioides difficile (C. diff) infection in individuals 18 years of age and older, following antibiotic treatment for recurrent C. diff infection REBYOTA is now available by prescription in the United States Ferring is committed to maki...